Biogen announced it will acquire Apellis Pharmaceuticals for approximately $5.6 billion in cash, plus contingent payments tied to sales milestones of Apellis' drug SYFOVRE®. The acquisition adds two FDA-approved immunology medicines, EMPAVELI® and SYFOVRE®, which generated $689 million in 2025 revenue and are expected to grow significantly through 2028. This deal enhances Biogen's portfolio in immunology and rare diseases, accelerates its entry into nephrology with Apellis' expertise, and is expected to boost Biogen's earnings starting in 2027. The transaction is set to close in Q2 2026, with Biogen financing it through cash and borrowings while aiming to maintain financial flexibility.
Biogen Inc. announced the appointment of Michael J. Parini as its new Chief Legal Officer, effective August 3, 2026. Parini brings over 20 years of legal and strategic leadership in the biopharmaceutical industry, having held senior roles at Spur The...
The LEADER study found that nearly 83% of early Alzheimer's patients remained stable or improved while on LEQEMBI treatment for an average of 17 months, consistent across demographics and genetic profiles. LEQEMBI targets amyloid beta to slow cogniti...
Biogen announced positive Phase 2 results for diranersen, an antisense therapy targeting tau protein in early Alzheimer's disease. The study showed meaningful clinical benefits, including slowing cognitive decline by up to 50% on some measures, and r...
The FDA has approved LEQEMBI IQLIK, a once-weekly subcutaneous injection for initiating treatment of early Alzheimer's disease, allowing at-home dosing. This new form offers a convenient alternative to intravenous infusions, providing flexibility for...
Biogen's stock received an upgrade as investors anticipate the company's upcoming announcement of detailed data from its Phase 2 study on an experimental Alzheimer's drug. This data release is significant because it could impact the future of Alzheim...
